Industry: Small-molecule therapeutics

Nox2 is developing a new drug to treat asthma and other inflammatory lung diseases. The company is exploring small-molecule therapeutics that inhibit myleperoxidase, or Nox2. The inhibitors reduce levels of reactive oxygen in cells and tissue.
The company’s lead molecule for drug discovery is a sub-micromolar inhibitor that has shown to be effective in animal models of lung inflammation. In vitro tests on this molecule have demonstrated good results.
The asthma therapy market exceeds $15 billion annually, and a new first-in-class drug would likely capture a significant share of this market. Nox2’s therapy may also address other inflammatory conditions, such as Acute Respiratory Distress Syndrome and Chronic Obstructive Pulmonary Disease, for which current treatments are inadequate.

Back to companies